Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Letters   |    
Tardive Dyskinesia Induced by a Switch From Haloperidol Depot to Paliperidone Palmitate
Chih-Yao Hsu, M.D.; Ya-Hui Lin, O.T.; Yu-Chih Shen, M.D., Ph.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2013;25:E46-E47. doi:10.1176/appi.neuropsych.12110278
View Author and Article Information

The authors declare no conflict of interest.

Dept. of Psychiatry, Tzu-Chi General Hospital, Hualien, Taiwan (C-YH, Y-HL, Y-CS), Dept. of Psychiatry, School of Medicine and Dept. of Human Development, College of Humanities and Social Sciences, Tzu Chi University, Hualien, Taiwan (Y-CS)

Correspondence: Yu-Chih Shen, M.D., Ph.D.; e-mail: shengmp@gmail.com

Copyright © 2013 by the American Psychiatric Association


To the Editor: Tardive dyskinesia (TD) is a movement disorder that can occur during antipsychotic medication use, occasionally after many months, but, more commonly, after years.1 It is usually associated with older patient age, female gender, longer duration, and higher dosages of antipsychotic treatment, concurrent affective disorders, and greater severity of the psychotic disorder.2 With the increasing use of atypical antipsychotics, fewer cases and less severe symptoms of TD have been seen.3 For this reason, patients on typical antipsychotics are generally switched to atypical antipsychotics if possible. Furthermore, there is evidence that atypical antipsychotics may improve TD symptoms without causing progression of this disorder.4 We report here an unusual condition in which a schizophrenic patient developed TD after switching her antipsychotic medication from haloperidol depot to paliperidone palmitate. The TD was then successfully resolved by using aripiprazole instead.

Figures in this Article

First Page Preview

View Large
First page PDF preview
Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).



Margolese  HC;  Chouinard  G;  Kolivakis  TT  et al:  Tardive dyskinesia in the era of typical and atypical antipsychotics, part 2: incidence and management strategies in patients with schizophrenia.  Can J Psychiatry 2005; 50:703–714
Tenback  DE;  van Harten  PN:  Epidemiology and risk factors for (tardive) dyskinesia.  Int Rev Neurobiol 2011; 98:211–230
Dolder  CR;  Jeste  DV:  Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients.  Biol Psychiatry 2003; 53:1142–1145
[CrossRef] | [PubMed]
Peritogiannis  V;  Tsouli  S:  Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? case report and brief review of the literature.  J Psychopharmacol 2010; 24:1121–1125
[CrossRef] | [PubMed]
Schultz  SK;  Miller  DD;  Arndt  S  et al:  Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.  Biol Psychiatry 1995; 38:713–719
[CrossRef] | [PubMed]
Liskowsky  DR;  Potter  LT:  Dopamine D2 receptors in the striatum and frontal cortex following chronic administration of haloperidol.  Neuropharmacology 1987; 26:481–483
[CrossRef] | [PubMed]
Citrome  L:  Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.  Expert Opin Drug Metab Toxicol 2012; 8:873–888
[CrossRef] | [PubMed]
Hough  D;  Gopal  S;  Vijapurkar  U  et al:  Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.  Schizophr Res 2010; 116:107–117
[CrossRef] | [PubMed]
Lally  J;  Byrne  F;  Walsh  E:  A case of paliperidone-palmitate-induced tardive dyskinesia.  Gen Hosp Psychiatry 2012; 35:213; available at doi: 10.1016/j.genhosppsych.2012.04.009
Wei  HT;  Lai  YW;  Chen  MH  et al:  Oral-paliperidone-induced tardive dyskinesia: a case report.  Gen Hosp Psychiatry 2012; 34:e5–e6
[CrossRef] | [PubMed]
Teng  PR;  Lai  TJ:  Paliperidone-related rabbit syndrome.  J Clin Psychopharmacol 2011; 31:379–380
[CrossRef] | [PubMed]
Pandina  GJ;  Lindenmayer  JP;  Lull  J  et al:  A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.  J Clin Psychopharmacol 2011; 31:379–380
[CrossRef] | [PubMed]
References Container

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
APA Practice Guidelines > Chapter 4.  >
APA Practice Guidelines > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 34.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
Topic Collections
Psychiatric News
PubMed Articles